Pod Insights Motley Fool Hidden Gems Investing Has Biotech Met Its Moment? About this episode A surge in private market investment has Fools wondering: is it time to bet bigger on biotech? Tim Beyers and Karl Thiel discuss: - The rise in biotech funding from VCs and wealthy individuals. - The key attributes of an investable biotech. - Which is the better biotech: Viking Therapeutics or Eli Lilly? Companies discussed: VKTX, LLY, MRK Host: Tim Beyers and Karl Thiel Producer: Anand Chokkavelu Engineer: Dan Boyd, Natasha Hall Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Transcript 0:05 Speaker 00 Is it time to buy biotech? You're listening to Motley Fool Money.
0:21 Speaker 00 Fools, welcome to Motley Fool Money for Monday, July 21, 2025. I'm your host, Tim Beyers. With me, Carl Thiel from the Rule Breakers team. Welcome to your Rule Breakers podcast. Carl, how you feeling this morning? Ready to talk biotech? Caffeinated, I hope?
0:36 Speaker 01 Absolutely. Plenty caffeinated.
0:38 Speaker 00 Plenty caffeinated. I can't ever be too caffeinated. We want to bring this up because we have recent data from LARCA that the total VC funding in biotech increased year over year for the first time since 2021. This is last year, reaching 21.4 billion versus 16.1 billion in 2023. That was a significant increase. Now, that surpassed pre-pandemic levels. Furthermore, 2024 recorded the strongest quarter since early 2022. This has seemed to continue, Carl. Like 2024, we ended really strong, but then just recently, the Narcan maker, which is
1:20 Speaker 00 a kind of an anti-narcotic, I don't really know how to describe it here, but a company named Anthea raised 56 million in Series C capital. And we also have some data that family offices are committing in bigger amounts to biotech, an early-stage biotech. So here's my question for you, Carl. Before we get into the opportunity in biotech, how are you feeling about this? The private market seems to like biotech more than it has in a while. Is that something we can look forward to as public market biotech investors?
1:58 Speaker 01 So I guess my overall feeling, and this may come through a few different ways and to a lot of things we talk about today, it's guarded optimism with lots of caveats, basically.
2:14 Speaker 01 I'm glad to see venture capital. I have to say, to me, when you look at it, it's more like it's stabilizing than that I really see a lot of things going up. I mean, if you look ahead of the 2024 data, the second quarter of this year looks like it's actually going to come in at a five-quarter low. It dropped back down again. I'm not terribly worried about that. I mean, but I think what you're seeing is this stabilization and this kind of weighting. But you brought up family offices, and that's a really interesting, and for people who don't
2:59 Speaker 01 know, I mean, these are sort of, you know, very wealthy
3:02 Speaker 00 Yeah, high net worth individuals.
3:03 Speaker 01 private investors, right, who are, or who get, you know, they tend to, I would say that in the past, family offices have been, they've often been passion projects when they invest in the sector. You know, maybe somebody in the family had a particular disease and they want to put money into that disease, something like that. These days, the investments are getting bigger and they are often, different family offices are working together, or sometimes they're working with a general partner. I feel that they're sort of stepping into the void because they have even longer timelines than a traditional VC. Their timelines are as long as they want them to be. They are kind of stepping into the void to take care
3:48 Speaker 01 of some of the really early seed stuff. And Anthea is a really interesting company. Eric Schmidt from Google is involved in that one. But, you know, that's a fascinating company and just the perfect kind of thing for a family office to be involved in.
4:06 Speaker 00 Yeah, I mean, this is super interesting. Let's pivot to the opportunity because, again, we said that biotech has been really hit or miss. It's a big part of the Motley Fool Rule Breakers scorecard has been just short of forever, really since the beginning of the service over 20 years ago. So I want to talk about this because it has been hit or miss. We've twice recommended the XBI, which is a biotech-themed ETF, and both positions have lost to the market by 35% and 60% as, you know, our recording.
4:43 Speaker 00 Why is now a more interesting time in addition to all of this activity in the private market and we're starting to see more IPOs? Why is now an interesting time for you as a biotech investor? What should get the public market investors more excited about this?
5:02 Speaker 01 Yeah, well, I think our XBI positions are sort of reflective of what's going on in the broader market, which is that in absolute terms, those positions aren't down sharply. I think last
5:16 Speaker 00 No, they're just losing to the market. Right.
5:19 Speaker 01 They're just losing to the market. And that's kind of exactly what you're seeing, which is, as with the VC funding, biotech's kind of moving sideways right now. And for a while, the markets were moving sharply higher. There's been some more volatility around that. But the question, why is this a good time to be investing in biotech? I think, let me first briefly say why everything continues to be so negative. The reasons to be negative before were high interest rates, lack of M and A, this sort of overdraft of companies that came public when they shouldn't have early on, that the
6:02 Speaker 01 market was still digesting and just the slop that needed to get out of the system. Some of those are getting a little bit better. We actually have seen some really interesting M and A this year, a lot of multi-billion dollar deals, and that's super bullish. But at the same time, some of those are still in place. And then we've got a new collection of worries around what's going on at the FDA and how are they going to regulate things? And what's going on with pricing and the political environment? All those things are still hanging over the sector. So to be a real bull right now, you do have to be a little bit contrarian and kind of look at a wall of worry that you think this market can climb.
6:43 Speaker 01 I mean, there's still plenty of reasons to be cautious that you can point out. And to the XBI in particular, I guess the reason I've been a little less personally focused on the XBI, I mean, it is a proxy for the whole sector that people, that's sort of the commonly used tool to say, how is biotech doing? Let's look at the XBI. But it's a very broad index. It's got this kind of Equal weighting formula so that it's getting rebalanced all the time and doesn't favor the large, large cap companies. I think it's a better time, honestly, for taking very careful picks within the sector rather than just broad market exposure.
7:27 Speaker 01 The broad market exposure pays off when things finally turn around. And I do think that happens eventually, but I think, you know, you can maybe do better picking carefully individual companies that can not only get a sort of general industry lift, but also have, you know, some of their own specific things going on that are underappreciated.
7:49 Speaker 00 There's two things I've heard you say to me about when you're talking about biotechs that you want to maybe focus in on that might be an interesting play, like ones that we want to add to the rule breaker scorecard, for example. Two things that I have heard from you. One is if the science is really good and the way and the capital that the company has is good enough, that is, that's a company that's giving itself runway to maybe get to scale and develop a blockbuster drug. That may be a worthwhile risk. So that's one I've heard you talk about.
8:29 Speaker 00 The other is when there's enough there, there that the vulture that could come along and acquire this company at a premium, you know, might be salivating a little bit more. And those, those two things sort of create the conditions for really good potential biotech returns. Do you think we're seeing more of those types of situations right now?
8:54 Speaker 01 I think you're seeing a situation in which, in terms of buying out companies, in which Big Pharma has been a little bit sitting on the sidelines, but they, they can't really afford to keep doing that. And so there's companies like Merck has been sort of very open about, you know, that they are out shopping, the wallet is open, they are looking around, you know, they, they can't put off forever, ever filling in pipelines. There is a lot of big, big cliff, patent cliff situations going on at most of the Big Pharma companies.
9:30 Speaker 00 And a patent cliff, meaning like a drug that is under patent, but going to be forced to become generic?
9:39 Speaker 01 Exactly. So you see companies that have, you know, 20, 30, 40, 60% of their revenue is going to, you know, essentially open up to generic competition and largely disappear over the next few years. Yeah, it's a big deal. So that's one thing. But I guess the other thing I'd say into what you just said is, you know, do they have the science and do they have the cash? Yes, I would add to that right now. I think you have to be even more picky, which is, do they have the science? Do they have the cash? And are they pretty close to market right now? You know, having great science.
10:16 Speaker 00 Through to approval, almost.
10:18 Speaker 01 Right. You've got to see a, you've got to see a through line. I just think there's enough opportunities like that, that you don't need to play the hero with with earlier stage science. I mean, there's obviously, there's going to be some great payoffs there, but like, risk adjusted, I feel like there are a lot of very late stage companies that are, that are near market, on the market, or even on the market and already seeing sharp sales ramps that you can kind of more focus there.
10:44 Speaker 00 Fair enough. All right, we're going to talk about two of them. Up next, which is the better biotech? Viking or Eli Lilly? We're going to battle it out next.
10:56 Speaker 02 Traders don't need a prettier app. They need a better angle. Think or Swim from Schwab is packed with tools that real traders use, like over 300 chart studies, customization to fit your trading style, and integrated risk management technology. Because when it comes to trading, Schwab knows it's about more than just a single click. It's about everything that went into it. Learn more at schwab.com/trading.
11:26 Speaker 00 All right, Carl, let's talk about two companies that you mentioned not playing the hero, you know, companies that have drugs that are either on the market or very, very close to on the market. And we've got a mixture of both, you know, on the market, Eli Lilly has done exceptionally well with
11:48 Speaker 00 Weight loss drugs, Mounjaro and Zepbound, they are the strong rivals to one that fools you certainly have heard of called Ozempic. But Viking has a late-stage drug, actually more than one late-stage drug, that is interesting and competing in this space. So Carl, break it down for us here. You know, when you look at these two, give me, give me one advantage and one disadvantage of, of each. Or if you want to, just tell me, which of these two do you favor?
12:21 Speaker 01 Look, if you're oriented towards, you know, safety and stability, Lilly is plainly the better company to go with here. I mean, they're not only winning in the marketplace, I mean, you know, Mounjaro and Zepbound have surpassed Ozempic. They also have a tremendous follow-on pipeline. I mean, when, when you look at who are developing the, the best next-generation sort of GLP and related drugs, often they're, they're more than one mechanism. It's GLP plus other mechanisms. Lilly is not necessarily at the top in every category, but they're, they're always near the top. They've really done a great, great
13:04 Speaker 01 job in this area. Not to mention the fact that they are a diverse pharmaceutical company with, with, you know, lots of other things going on in other areas. That said, you know, right now, the market is essentially a duopoly between Lilly and Novo Nordisk. And, you know, largely about two products, even though there's a few brand name floating around, it's really just two compounds, terzepatide and semaglutide. That is not always going to be this way. And the, the discontinuation rates of these drugs over like a one and two-year period is, is horrific. I mean, people just, you know, they're not staying on them, which tells
13:43 Speaker 01 you something about the, the sort of long-term wear of the side effects of these drugs. So there's a lot of room for improvement and there's a lot of companies vying to do it. I think Viking is a super interesting pick in the space. I will say, you know, when I talk about companies that are sort of like on the verge of, of going to market, This is not one of them. They've got a lot of work ahead of them. They are late-stage. They are late-stage. They began their phase three in their injectable formulation of their drug. Their oral drug is a little bit farther behind. You know, we'll see data in the next couple of years.
14:25 Speaker 01 But, you know, it still remains to me a relatively speculative bet. That said, it's one where, you know, if you're looking for maximum returns, I mean Viking is tiny, tiny, tiny compared to Lilly. Could see absolutely massive returns. And this would be one that, to me, you would slot in as a speculative bet in a larger portfolio.
14:50 Speaker 00 I mean, and we sometimes like that in rule breakers. Let me put you on the spot here and say of these two, actually, before I put you on the spot here, do you think that Viking is a pretty good M&A candidate? Does it fit into that theme of biotechs that are really producing good science? Have the cash? Very attractive. Somebody to come in and swoop this one up?
15:17 Speaker 01 Oh, it absolutely is. I mean, there's been a tremendous amount of M&A in the sector. I mean, specifically around the obesity space. I mean, companies have been snapped up. And when you look at large pharma that have great needs in the area, like Pfizer, for instance, needs products. Their own obesity programs flamed out. You know, you would think they would certainly be in the market to be buying.
15:43 Speaker 01 And they're not the only ones. That said, Viking has not shown much interest in being acquired so far. So I'm sure these conversations are taking place. But, you know, and so I assume that Viking is driving a very, very hard bargain. They do have really good data to date. It's early data, so, you know, I don't want to overestimate it, but it's really good. I think they're very confident in the product and they are a little bit farther ahead than most people. So I think they're going to ask for a big price tag.
16:15 Speaker 00 Who are you going with then? So are you going with Viking or are you going with Lilly? So outperforming over the next five years, who you got?
16:23 Speaker 01 So outperforming, yeah, I will go with Viking just because I mean, if they hit with this, there's, you know, there's no way Lilly is going to be able to, yeah, to, you know, Lilly is not going to
16:35 Speaker 00 If they hit, it's a monster.
16:36 Speaker 01 Quin-tuple.
16:37 Speaker 00 Right.
16:37 Speaker 01 Right, right, exactly.
16:39 Speaker 00 Yeah.
16:39 Speaker 01 But it is certainly way, way riskier.
16:41 Speaker 00 Yeah, I'm going with Viking as well. If this is, this is a classic rule breaker. If it hits, it will be a massive multi-bagger. So Viking Therapeutics, the ticker is VKTX. All right, up next, a little trivia. Get your notepad ready and let us know in the comments. What company is generally considered history's first biotech? We're coming back with that next.
17:09 Speaker 03 Get a concise daily market preview from Charles Schwab, including stock updates, U.S. and global economic news, monetary policy decisions, and key results and statistics that may impact your trading. Schwab Market Update is an original podcast from Charles Schwab. Join host Keith Lanceford for this information-packed daily market preview delivered in 10 minutes or less. Listen today at schwab.com/marketupdatepodcast or wherever you get your podcasts. That's schwab.com/marketupdatepodcast.
17:41 Speaker 00 All right, Carl. So as always, I like to end these with a little bit of trivia, a little bit of history, try to help members understand a little bit more about the market we're talking about. In this case, we've been talking about the biotech market. I'm super curious of your answer here, and I've got a little bit of detail that we'll talk about after I get your answer. But fools, go ahead and give your answer in the comments. What company is generally considered history's first biotech? Carl, what is your answer on this? I am really interested to hear what you say.
18:15 Speaker 01 Well, I'm interested to hear what you're gonna say. I think there's only two possible answers here, and I'm pretty clear on which it is. You could argue that it's Genentech, but I think it's pretty clearly Cedis Corp.
18:30 Speaker 00 Okay, very interesting. So, we need to hear more about Cedis Corp. Because when I put this to Gemini, Gemini said, and I'm quoting here, "Well, biotechnology broadly defined has roots in ancient practices like brewing and fermentation. The birth of the modern biotech industry focused on genetic engineering is generally associated with the founding of Genentech, founded in 1976 by Herbert Boyer and venture capitalist Robert Swanson." So, tell me more about Cedis.
19:00 Speaker 01 Yeah, so, Genentech, the argument for that is that they were specifically founded to take care, to take advantage of your recombinant DNA techniques to make proteins that you, you know, you couldn't manufacture otherwise. Cedis Corp. was founded five years before that in 1971.
19:20 Speaker 00 Yeah, 1971, yeah.
19:22 Speaker 01 Yeah, and it was, it was basically a microbiology company that was set up, you know, initially what they were doing was more sort of industrial, making enzymes and stuff, but they became a biotech giant. One of their products is still on the market today, Proleucin, and they are the ones who developed PCR, specifically Carey Mullis at Cedis Corp., who I got to interview once, Nobel laureate, developed the polymerase chain reaction, which is the DNA amplification technique that is still core today for most gene sequencing. And if nothing else, I think that cements them as the first company.
20:05 Speaker 00 So, interestingly enough, that Gemini did mention Cedis, but it mentioned Cedis as, as the runner-up. I was super curious about this, because I think I've told you this, even though I've learned more about biotech from you than anybody else, my grandfather was a research, a research doctor at Squibb back in the 1950s and 1960s. So, I thought like, I have thought, not that Squibb would be the first biotech, but it would be like, well, surely this goes back to like the 1930s or 1940s, but nope, it's the 1970s. So, this is still a relatively new industry. We're really...
20:44 Speaker 00 You know, if you want to count Cetus, we're 54 years into the into the industry. That makes us a fairly young industry.
20:53 Speaker 01 Absolutely. Yeah. And, and, you know, a lot of the, some of the pioneers are still around. There are companies, I mean, I was just looking Sarepta, SRPT, is in the news a lot right now, not for good reasons, but for interesting reasons. But I mean, that's another, that's just an example of a company that's its original DNA goes back to 1980, right? There's a lot. Biogen goes back to 1970. I mean, it's, it's, a lot of these first generation companies are still what's cooking today.
21:28 Speaker 00 And still, and still cooking and still going. All right, Carl, thanks for, thanks for being here. Thanks for talking biotech. Appreciate that. Fools, as always, people on the program may have interests in the stocks they talk about, and the Motley Fool may have formal recommendations for or against. So don't buy or sell stocks based solely on what you hear. All personal finance content follows Motley Fool editorial standards and is not approved by advertisers. Advertisements are sponsored content provided for informational purposes only. To see our full advertising disclosure, please check our show notes. For our engineer, Dan Boyd, for our producer, Anan Chakavalu, for Carl Teal, I'm Tim Beyers.
22:12 Speaker 00 Fools, thank you for tuning in. See you again tomorrow. Bulaan.
Previous Roland Rott, CEO of GE Healthcare Imaging on AI Next Block Party and Big Swings Page updated November 16, 2026 · transcript and summary are machine-generated